If indeed PEDF represents an important regulatory node in the RASopathies, the effects of neurofibromin loss should be mitigated by PEDF restoration, and thus represent a potential adjuvant therapeutic strategy for NF1 melanoma. This evidence concerns the gene SERPINF1 and neurofibromatosis type 1.